FDA DEVICE FACTS
Monocryl Plus Antibacterial Suture
ETHICON, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
MONOCRYL™ Plus Antibacterial Sutures are indicated for use in general soft tissue approximation and/or ligation, but not for use in cardiovascular or neurological tissues, microsurgery or ophthalmic surgery.
Summary of Technological Characteristics and Performance:
The modified MONOCRYL™ Plus Suture has the same technological characteristics as the predicate device. Like the currently marketed predicate device, it is a sterile, monofilament synthetic absorbable suture that complies with the requirements of the United States Pharmacopoeia (USP) for absorbable surgical sutures except for a slight oversize in diameter.
Like the current marketed MONOCRYL™ Plus Antibacterial Suture, the modified device will continue to be available as a suture product with Irgacare®‡ MP, an antibacterial agent.
In vitro efficacy studies were conducted to demonstrate that bacteria will not colonize MONOCRYL™ Plus Antibacterial suture. The in vitro data indicated that MONOCRYL™ Plus suture provides an antibacterial effect sufficient to inhibit colonization of the suture by Staphylococcus aureus, Staphylococcus epidermidis, Methicillin-Resistant S. aureus, Methicillin- Resistant S. epidermidis, Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。